The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma

Surgery Today

Volumn 41, Issue 6, 2011, Pages 818-823

  Kawano, Daigo ^a   Yano, Tokujiro ^a   Shoji, Fumihiro ^a   Ito, Kensaku ^a   Morodomi, Yosuke ^a   Haro, Akira ^a   Miura, Naoko ^a   Takenaka, Tomoyoshi ^a   Yoshino, Ichiro ^b   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor; Gefitinib; Hepatocyte growth factor; Intrinsic resistance; Met proto oncogene

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 9; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; ONCOPROTEIN; SCATTER FACTOR;

ARTICLE; CANCER RECURRENCE; CELL LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; ONCOGENE; POSTOPERATIVE PERIOD; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 79960320349     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-4514-2     Document Type: Article

References (25)

1. A. Iyoda K. Hiroshima Y. Moriya 2010 Predictors of postoperative survival in patients with locally advanced non-small cell lung carcinoma Surg Today 40 725 728 20676855 10.1007/s00595-009-4127-1
2. D.S. Salomon R. Brandt F. Ciardiello 1995 Epidermal growth factorrelated peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 183 232 7612182 10.1016/1040-8428(94)00144-I 1:STN:280:DyaK2Mzjs1KgsQ%3D%3D
3. J. Mendelsohn J. Baselga 2000 The EGF receptor family as targets for cancer therapy Oncogene 19 6550 6565 11426640 10.1038/sj.onc.1204082 1:CAS:528:DC%2BD3MXhsF2ku7k%3D (Pubitemid 32197693)
4. G. Selvaggi S. Novello V. Torri 2004 Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann Oncol 15 28 32 14679115 10.1093/annonc/mdh011 1:STN:280:DC%2BD3srps1Kntw%3D%3D (Pubitemid 38139599)
5. M. Fukuoka S. Yano G. Giaccone 2003 Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237 2246 12748244 10.1200/JCO.2003.10.038 1:CAS:528:DC%2BD2cXpsVGqu7w%3D (Pubitemid 46621858)
6. M.G. Kris R.B. Natale R.S. Herbst 2003 Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2149 2158 14570950 10.1001/jama.290.16.2149 1:CAS:528:DC%2BD3sXosVOnsbo%3D (Pubitemid 37432975)
7. T.J. Lynch D.W. Bell R. Sordella 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
8. J.G. Paez P.A. Janne J.C. Lee 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
9. T. Mitsudomi Y. Yatabe 2007 Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 1817 1824 17888036 10.1111/j.1349-7006.2007.00607.x 1:CAS:528:DC%2BD2sXhsVahtbbF (Pubitemid 350002184)
10. A. Inoue T. Suzuki 2006 Prospective phase II study of gefitinib for chemotherapy-naïve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 3340 3346 16785471 10.1200/JCO.2005.05.4692 1:CAS:528:DC%2BD28Xot1Kis7g%3D (Pubitemid 46638887)
11. S. Kobayashi T.J. Boggon T. Dayaram 2005 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 786 792 15728811 10.1056/NEJMoa044238 1:CAS:528:DC%2BD2MXhsFCiurk%3D (Pubitemid 40271173)
12. W. Pao V.A. Miller K.A. Politi 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 e73 15737014 10.1371/journal.pmed.0020073 (Pubitemid 40629469)
13. J.A. Engelman K. Zejnullahu T. Mitsudomi 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 1039 1043 17463250 10.1126/science.1141478 1:CAS:528:DC%2BD2sXltlOjt7g%3D (Pubitemid 46799492)
14. J. Bean C. Brennan J.Y. Shih 2007 MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci USA 104 20932 20937 18093943 10.1073/pnas.0710370104 1:CAS:528:DC%2BD1cXktlyhsg%3D%3D
15. P. Therasse S.G. Arbuck E.A. Eisenhauer J. Wanders 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, N ational Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
16. Y. Nakamura T. Niki A. Goto 2007 c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis Cancer Sci 98 1006 1013 17459054 10.1111/j.1349-7006.2007.00493.x 1:CAS:528:DC%2BD2sXnsVOqsrk%3D (Pubitemid 46865384)
17. S.W. Han P.G. Hwang D.H. Chung 2005 Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1939) in chemotherapy-resistant non-small cell cancer Int J Cancer 113 109 115 15386420 10.1002/ijc.20550 1:CAS:528:DC%2BD2cXhtVWgsL7P (Pubitemid 39507317)
18. D. Matsuya C. Huang D. Liu 2004 The tumor-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumor growth and prognosis in non-smallcell lung cancer patients Br J Cancer 90 1555 1562 10.1038/sj.bjc.6601718 (Pubitemid 38648238)
19. F.R. Hirsch M. Varella-Garcia P.A. Bunn 2003 Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J Clin Oncol 21 3798 3807 12953099 10.1200/JCO.2003.11.069 1:CAS:528:DC%2BD2cXpsVKisL8%3D (Pubitemid 46606235)
20. T. Suzuki T. Nakagawa H. Endo 2003 The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ("Iressa") is not related to the expression of EGFR or HER-2 or to K-ras gene status Lung Cancer 42 35 41 14512185 10.1016/S0169-5002(03)00278-2 (Pubitemid 37153133)
21. S. Yano W. Wang Q. Li K. Matsumoto 2008 Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations Cancer Res 68 9479 9487 19010923 10.1158/0008-5472.CAN-08-1643 1:CAS:528:DC%2BD1cXhtlOmt7jE
22. J.Y. Wu S.G. Wu C.H. Yang C.H. Gow 2008 Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response Clin Cancer Res 14 4877 4882 18676761 10.1158/1078-0432.CCR-07-5123 1:CAS:528:DC%2BD1cXpt1eju7w%3D
23. X. Zang J. Gureasko K. Shen P.A. Cole 2006 An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 1137 1149 10.1016/j.cell.2006.05.013 (Pubitemid 43866200)
24. E.R. Wood A.T. Truesdale O.B. McDonald D. Yuan 2004 A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 6652 6659 15374980 10.1158/0008-5472.CAN-04-1168 1:CAS:528:DC%2BD2cXnsFOlu7g%3D (Pubitemid 39297926)
25. S.H. Choi J.M. Mendrola M.A. Lemmon 2007 EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer Oncogene 26 1567 1576 16953218 10.1038/sj.onc.1209957 1:CAS:528:DC%2BD2sXisFynsbw%3D (Pubitemid 46398741)